A biased ligand for OXE-R uncouples Gα and Gβγ signaling within a heterotrimer

The first small-molecule inhibitor of chemoattractant GPCR OXE-R disrupts signaling downstream of Gβγ but not Gα i/o , providing evidence that signaling bias can occur between Gβγ and Gα subunits within a heterotrimer. Differential targeting of heterotrimeric G protein versus β-arrestin signaling ar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature chemical biology 2012-07, Vol.8 (7), p.631-638
Hauptverfasser: Blättermann, Stefanie, Peters, Lucas, Ottersbach, Philipp Aaron, Bock, Andreas, Konya, Viktoria, Weaver, C David, Gonzalez, Angel, Schröder, Ralf, Tyagi, Rahul, Luschnig, Petra, Gäb, Jürgen, Hennen, Stephanie, Ulven, Trond, Pardo, Leonardo, Mohr, Klaus, Gütschow, Michael, Heinemann, Akos, Kostenis, Evi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The first small-molecule inhibitor of chemoattractant GPCR OXE-R disrupts signaling downstream of Gβγ but not Gα i/o , providing evidence that signaling bias can occur between Gβγ and Gα subunits within a heterotrimer. Differential targeting of heterotrimeric G protein versus β-arrestin signaling are emerging concepts in G protein–coupled receptor (GPCR) research and drug discovery, and biased engagement by GPCR ligands of either β-arrestin or G protein pathways has been disclosed. Herein we report on a new mechanism of ligand bias to titrate the signaling specificity of a cell-surface GPCR. Using a combination of biomolecular and virtual screening, we identified the small-molecule modulator Gue1654, which inhibits Gβγ but not Gα signaling triggered upon activation of Gα i -βγ by the chemoattractant receptor OXE-R in both recombinant and human primary cells. Gue1654 does not interfere nonspecifically with signaling directly at or downstream of Gβγ. This hitherto unappreciated mechanism of ligand bias at a GPCR highlights both a new paradigm for functional selectivity and a potentially new strategy to develop pathway-specific therapeutics.
ISSN:1552-4450
1552-4469
DOI:10.1038/nchembio.962